Throughout the COVID-19First identified in 2019 in Wuhan, China, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread globally, resulting in the 2019–20 coronavirus pandemic.”>COVID-19 pandemic, there has been much uncertainty about how long immunity lasts after an unvaccinated person is infected with SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the official name of the virus strain that causes coronavirus disease (COVID-19). Previous to this name being adopted, it was commonly referred to as the 2019 novel coronavirus (2019-nCoV), the Wuhan coronavirus, or the Wuhan virus.”>SARS-CoV-2.
Now a team of scientists led by faculty at Yale School of Public Health and the University of North Carolina at Charlotte have an answer: Strong protection following natural infection is short-lived.
“Reinfection can reasonably happen in three months or less,” said Jeffrey Townsend, the Elihu Professor of Biostatistics at the Yale School of Public Health and the study’s lead author. “Therefore, those who have been naturally infected should get vaccinated. Previous infection alone can offer very little long-term protection against subsequent infections.”
The study, published in the journal The LancetFounded in 1823 by Thomas Wakley, The Lancet is a weekly peer-reviewed general medical journal. It is one of the world’s oldest, most prestigious, and best known general medical journals. The journal publishes original research articles, review articles (“seminars” and “reviews”), editorials, book reviews, correspondence, as well as news features and case reports. The Lancet has editorial offices in London, New York, and Beijing. ”>The Lancet Microbe, is the first to determine the likelihood of reinfection following natural infection and without vaccination.
Alex Dornburg, assistant professor of bioinformatics and genomics at the University of North Carolina at Charlotte. Credit: UNC Charlotte
Townsend and his team analyzed known reinfection and immunological data from the close viral relatives of SARS-CoV-2 that cause “common colds,” along with immunological data from SARS-CoV-1 and Middle East Respiratory Syndrome. Leveraging evolutionary principles, the team was able to model the risk of COVID-19 reinfection over time.
Reinfections can, and have, happened even shortly after recovery, the researchers said. And they will become increasingly common as immunity wanes and new SARS-CoV-2 variants arise.
“We tend to think about immunity as being immune or not immune. Our study cautions that we instead should be more focused on the risk of reinfection through time,” said Alex Dornburg, assistant professor of bioinformatics and genomics at the University of North Carolina at Charlotte, who co-led the study. “As new variants arise, previous immune responses become less effective at combating the virus. Those who were naturally infected early in the pandemic are increasingly likely to become reinfected in the near future.”
Alex Dornburg, assistant professor of bioinformatics and genomics at the University of North Carolina at Charlotte and Katerina Zapfe, a UNC Charlotte doctoral student. Credit: UNC Charlotte
The team’s data-driven model reveals striking similarities to the reinfection risks over time between SARS-CoV-2 and endemic coronaviruses.
“Just like common colds, from one year to the next you may get reinfected with the same virus,” Townsend said. “The difference is that, during its emergence in this pandemic, COVID-19 has proven to be much more deadly.”
A hallmark of the modern world is going to be the evolution of new threats to human health, Townsend added. Evolutionary biology — which provided the theoretical foundations for these analyses — is traditionally considered a historical discipline.
“However, our findings underscore its important role in informing decision-making, and provide a crucial steppingstone toward robust knowledge of our prospects of resistance to SARS-CoV-2 reinfection,” he said.
Reference: “The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study” by Prof Jeffrey P Townsend, PhD; Hayley B Hassler, MS; Zheng Wang, PhD; Sayaka Miura, PhD; Jaiveer Singh; Prof Sudhir Kumar, PhD; Prof Nancy H Ruddle, PhD; Prof Alison P Galvani, PhD and Alex Dornburg, PhD, 1 October 2021, The Lancet Microbe.
DOI: 10.1016/S2666-5247(21)00219-6
Co-authors include researchers from Temple University. Funding for the research was provided by the U.S. National Science Foundation.
Source: SciTechDaily
